Literature DB >> 15018830

Positron emission tomography/computed tomography of a rare xanthogranulomatous process: Erdheim-Chester disease.

Carlos Cunha Pereira Neto1, Chris Roman, Mahlon Johnson, Madan Jagasia, William H Martin, Dominique Delbeke.   

Abstract

Erdheim-Chester disease (ECD) is a disseminated xanthogranulomatous infiltrative disease of unknown etiology due to infiltration of different organs and bones by foamy histiocytes. A 37-year-old male with cerebral and periorbital lesions was diagnosed with this rare disease and was evaluated with magnetic resonance imaging (MRI) and 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) with positron emission tomography/computed tomography (PET/CT) imaging at baseline and following therapy. FDG-PET imaging allowed accurate evaluation of the extent of the disease at baseline, as well as assessment of response to therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15018830     DOI: 10.1016/j.mibio.2004.01.023

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  3 in total

1.  FDG-PET in the Erdheim-Chester disease: its diagnostic and follow-up role.

Authors:  Emőke Steňová; Boris Steňo; Pavol Povinec; František Ondriaš; Jana Rampalová
Journal:  Rheumatol Int       Date:  2010-12-07       Impact factor: 2.631

2.  Late-onset sporadic ataxia, pontine lesion, and retroperitoneal fibrosis: a case of Erdheim-Chester disease.

Authors:  E Salsano; M Savoiardo; S Nappini; E Maderna; B Pollo; D Chinaglia; U Guerra; G Finocchiaro; D Pareyson
Journal:  Neurol Sci       Date:  2008-09-20       Impact factor: 3.307

Review 3.  Neurological manifestations and neuroradiological presentation of Erdheim-Chester disease: report of 6 cases and systematic review of the literature.

Authors:  Florence Lachenal; François Cotton; Hélène Desmurs-Clavel; Julien Haroche; Hervé Taillia; Nadine Magy; Mohamed Hamidou; Juan Salvatierra; Jean-Charles Piette; Denis Vital-Durand; Hugues Rousset
Journal:  J Neurol       Date:  2006-10-24       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.